Publicaciones en colaboración con investigadores/as de Mayo Clinic (257)

2024

  1. Guidance for assessment of the inflammation etiologic criterion for the GLIM diagnosis of malnutrition: A modified Delphi approach

    Clinical Nutrition, Vol. 43, Núm. 5, pp. 1025-1032

  2. Guidance for assessment of the inflammation etiologic criterion for the GLIM diagnosis of malnutrition: A modified Delphi approach

    Journal of Parenteral and Enteral Nutrition, Vol. 48, Núm. 2, pp. 145-154

  3. Immediate and sustained terminal complement inhibition with ravulizumab in patients with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder

    Frontiers in Neurology, Vol. 15

  4. Pathophysiology of Myocardial Infarction With Nonobstructive Coronary Artery Disease: A Contemporary Systematic Review

    CJC Open, Vol. 6, Núm. 2, pp. 380-390

  5. Patients’ and caregivers’ perspective on challenges and outcomes with tube feeding: Analysis of home enteral nutrition survey data

    Clinical Nutrition ESPEN, Vol. 61, pp. 94-100

  6. Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study

    Future oncology (London, England), Vol. 20, Núm. 6, pp. 297-306

2023

  1. A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2

    Human Mutation, Vol. 2023

  2. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

    Nature Medicine, Vol. 29, Núm. 7, pp. 1867-1876

  3. A multi-national survey of experience and attitudes towards managing catheter related blood stream infections for home parenteral nutrition

    Clinical Nutrition ESPEN, Vol. 57, pp. 126-130

  4. A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk

    International Journal of Cancer, Vol. 152, Núm. 2, pp. 239-248

  5. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

    The Lancet Oncology, Vol. 24, Núm. 1, pp. 77-90

  6. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1370-1375

  7. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 7, pp. 1376-1382

  8. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

    Genome Medicine, Vol. 15, Núm. 1

  9. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions

    New England Journal of Medicine, Vol. 389, Núm. 22, pp. 2039-2051

  10. Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival

    Cancer Medicine, Vol. 12, Núm. 15, pp. 16142-16162

  11. Author Correction: Optical coherence tomography in coronary atherosclerosis assessment and intervention (Nature Reviews Cardiology, (2022), 19, 10, (684-703), 10.1038/s41569-022-00687-9)

    Nature Reviews Cardiology

  12. Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD

    Journal of the American Society of Nephrology : JASN, Vol. 34, Núm. 6, pp. 955-968

  13. Deferred Versus Performed Revascularization for Left Main Coronary Disease with Hemodynamic Significance

    Circulation: Cardiovascular Interventions, Vol. 16, Núm. 6, pp. E012700

  14. Erratum : World Allergy Organization Anaphylaxis Guidance 2020 [Japanese Journal of Allergology Vol.70 (2021) No.9 p.1211-1234]

    Arerugi = [Allergy], Vol. 72, Núm. 3, pp. 314